News

MYCOMUNE^® To Be Offered By AgriLabs

Lenexa, KS – Biomune Company of Lenexa, KS and Agri Laboratories of St. Joseph, MO have announced a distribution agreement that will allow AgriLabs the exclusive selling and marketing rights for Mycomune ^® . Mycomune ^® is the first and only USDA approved bacterin which aids in the prevention of mastitis caused by Mycoplasma bovis . Biomune Company developed the killed vaccine and received a USDA license in 2004.

Mycomune ^® aids in the prevention of mastitis caused by Mycoplasma bovis and reduces duration and severity of Mycoplasma bovis infection. Mycoplasma mastitis has experienced a dramatic rise in incidence and the potential economic loss to the producer can be extensive due to the lack of effective treatment for the disease, reduced milk production and the practice of culling infected cows. Because Mycoplasma mastitis is virtually untreatable, Mycomune ^® is recommended as a preventative strategy in a herd health vaccination program .

Mycomune^® is administered subcutaneously in the neck in a convenient 2 ml dose and does not require milk withholding after vaccination. A three-injection vaccination regimen administered at two to four week intervals prior to calving is recommended. Semi-annual revaccination is also recommended for a high level of protection. The withholding period prior to slaughter is 21 days. Mycomune is available now from AgriLabs in 10 and 50 dose bottles. For more information call 800-542-8916.

Biomune is a leading manufacturer of vaccines and bacterins for the animal health industry. Since its inception in 1988, the company's rapid growth has been marked by technology breakthroughs and new product introductions.

AgriLabs is a leading animal health sales and marketing organization with distribution throughout the U.S.